SE457958B - Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositioner - Google Patents
Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositionerInfo
- Publication number
- SE457958B SE457958B SE8406263A SE8406263A SE457958B SE 457958 B SE457958 B SE 457958B SE 8406263 A SE8406263 A SE 8406263A SE 8406263 A SE8406263 A SE 8406263A SE 457958 B SE457958 B SE 457958B
- Authority
- SE
- Sweden
- Prior art keywords
- hemin
- water
- arginine
- arginate
- acetone
- Prior art date
Links
- 229940025294 hemin Drugs 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 title 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 44
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 15
- 229930064664 L-arginine Natural products 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 241000097929 Porphyria Species 0.000 claims description 13
- 208000010642 Porphyrias Diseases 0.000 claims description 13
- 239000011877 solvent mixture Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 235000019766 L-Lysine Nutrition 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 6
- -1 hemin compound Chemical class 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 11
- 229910052742 iron Inorganic materials 0.000 description 11
- HINLFAQOKAHXOD-UHFFFAOYSA-N 2-propan-2-ylpent-4-enamide Chemical compound CC(C)C(C(N)=O)CC=C HINLFAQOKAHXOD-UHFFFAOYSA-N 0.000 description 10
- 238000001802 infusion Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 201000005060 thrombophlebitis Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000016761 Haem oxygenases Human genes 0.000 description 4
- 108050006318 Haem oxygenases Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010036182 Porphyria acute Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 4
- QSHWIQZFGQKFMA-UHFFFAOYSA-N porphobilinogen Chemical compound NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical class [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229940109738 hematin Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 108700016481 Acute Hepatic Porphyria Proteins 0.000 description 2
- 208000003914 Acute hepatic porphyria Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 108010067549 Methemalbumin Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 208000033552 hepatic porphyria Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000000320 mechanical mixture Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- WNDUPUMWHYAJOR-SADXPQEKSA-K (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WNDUPUMWHYAJOR-SADXPQEKSA-K 0.000 description 1
- ZCFFYALKHPIRKJ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(=C(C)C(=CC=3C(C)=C(CCC(O)=O)C(N=3)=C3)N2)C=C)=C(C)C(C=C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 ZCFFYALKHPIRKJ-UHFFFAOYSA-N 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 108010017500 Biliverdin reductase Proteins 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000033141 Porphyria variegata Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000003056 Vitamin B6 deficiency Diseases 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000004558 biliverdin reductase Human genes 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000002117 porphyrinogenic effect Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- HPOKESDSMZRZLC-UHFFFAOYSA-N propan-2-one;hydrochloride Chemical compound Cl.CC(C)=O HPOKESDSMZRZLC-UHFFFAOYSA-N 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08431398A GB2168354B (en) | 1984-12-12 | 1984-12-12 | Hemin compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8406263D0 SE8406263D0 (sv) | 1984-12-10 |
| SE8406263L SE8406263L (sv) | 1986-06-11 |
| SE457958B true SE457958B (sv) | 1989-02-13 |
Family
ID=10571084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8406263A SE457958B (sv) | 1984-12-12 | 1984-12-10 | Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositioner |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPH0647541B2 (fr) |
| AT (1) | AT389308B (fr) |
| BE (1) | BE901319A (fr) |
| CA (1) | CA1242713A (fr) |
| CH (1) | CH666273A5 (fr) |
| DE (1) | DE3446887C2 (fr) |
| FR (1) | FR2574662B1 (fr) |
| GB (1) | GB2168354B (fr) |
| LU (1) | LU85716A1 (fr) |
| NL (1) | NL192682C (fr) |
| SE (1) | SE457958B (fr) |
| SU (1) | SU1384188A3 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0645681B2 (ja) * | 1986-02-05 | 1994-06-15 | 美浜 久春 | 修飾ヘム |
| IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| RU2200016C2 (ru) * | 2000-11-09 | 2003-03-10 | Всероссийская научно-исследовательская опытная станция пантового оленеводства | Способ производства пантогематогена |
| RU2179027C1 (ru) * | 2000-12-18 | 2002-02-10 | Кочерга Олег Иванович | Гематоген |
| RU2186571C1 (ru) * | 2001-01-15 | 2002-08-10 | Карякин Александр Вадимович | Детские лекарственные формы, стимулирующие кроветворение |
| US7994217B2 (en) | 2002-05-02 | 2011-08-09 | Xanodyne Pharmaceuticals, Inc. | Prenatal multivitamin/multimineral supplement |
| RU2268058C2 (ru) * | 2004-03-29 | 2006-01-20 | Всероссийский научно-исследовательский институт пантового оленеводства (ВНИИПО) | Способ получения биологически активного продукта из пантов и крови оленя |
| RU2297841C2 (ru) * | 2005-07-01 | 2007-04-27 | Закрытое акционерное общество "Медицинский антидопинговый центр" | Лекарственное средство наружного применения и способ его получения |
| RU2611636C1 (ru) * | 2016-02-25 | 2017-02-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования Новосибирский государственный аграрный университет | Гематоген |
| RU2671633C1 (ru) * | 2017-11-30 | 2018-11-06 | Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" | Высокоэффективный гематоген |
| CN117546938B (zh) * | 2023-10-29 | 2026-03-27 | 华中农业大学 | 血红素在植物基/微生物基蛋白模拟肉食品及生物铁强化型饮品中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2912M (fr) * | 1963-07-24 | 1964-11-09 | Rech S Pharma E R P H A R Soc | Dichlorhydrate d'hématoporphyrinate de procaine. |
| JPS4930521A (fr) * | 1972-07-17 | 1974-03-19 | ||
| JPS5144623A (ja) * | 1974-10-14 | 1976-04-16 | Green Cross Corp | Chushayoasechirusarichirusanenno seiho |
| DE2527158A1 (de) * | 1975-06-18 | 1976-12-23 | Herz Eberhard | Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| JPS5780317A (en) * | 1980-11-05 | 1982-05-19 | Sumitomo Chem Co Ltd | Preparation of pharmaceutical composition for injection |
| JPS57209211A (en) * | 1981-06-18 | 1982-12-22 | Shiseido Co Ltd | Antimicrobial composition |
-
1984
- 1984-12-10 AT AT0390784A patent/AT389308B/de not_active IP Right Cessation
- 1984-12-10 SE SE8406263A patent/SE457958B/sv not_active IP Right Cessation
- 1984-12-12 GB GB08431398A patent/GB2168354B/en not_active Expired
- 1984-12-13 NL NL8403782A patent/NL192682C/nl not_active IP Right Cessation
- 1984-12-14 FR FR848419134A patent/FR2574662B1/fr not_active Expired - Lifetime
- 1984-12-19 BE BE0/214195A patent/BE901319A/fr not_active IP Right Cessation
- 1984-12-21 DE DE3446887A patent/DE3446887C2/de not_active Expired - Fee Related
- 1984-12-28 LU LU85716A patent/LU85716A1/fr unknown
-
1985
- 1985-01-07 CH CH45/85A patent/CH666273A5/de not_active IP Right Cessation
- 1985-01-09 SU SU3831925A patent/SU1384188A3/ru active
- 1985-01-23 JP JP60009302A patent/JPH0647541B2/ja not_active Expired - Fee Related
- 1985-02-06 CA CA000473658A patent/CA1242713A/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ATA390784A (de) | 1989-04-15 |
| FR2574662B1 (fr) | 1990-03-02 |
| SE8406263L (sv) | 1986-06-11 |
| BE901319A (fr) | 1985-04-16 |
| CH666273A5 (de) | 1988-07-15 |
| CA1242713A (fr) | 1988-10-04 |
| DE3446887A1 (de) | 1986-07-03 |
| NL192682C (nl) | 1997-12-02 |
| SU1384188A3 (ru) | 1988-03-23 |
| GB8431398D0 (en) | 1985-01-23 |
| SE8406263D0 (sv) | 1984-12-10 |
| FR2574662A1 (fr) | 1986-06-20 |
| AT389308B (de) | 1989-11-27 |
| DE3446887C2 (de) | 1994-05-05 |
| JPS61172821A (ja) | 1986-08-04 |
| NL8403782A (nl) | 1986-07-01 |
| LU85716A1 (fr) | 1985-07-24 |
| GB2168354B (en) | 1988-12-07 |
| GB2168354A (en) | 1986-06-18 |
| JPH0647541B2 (ja) | 1994-06-22 |
| NL192682B (nl) | 1997-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008100418A1 (fr) | Complexes de zinc d'acides aminés naturels pour le traitement de toxicités provoquées par un cuivre élevé | |
| EP0264278B1 (fr) | Compositions de vanadium et peroxyde comme médicaments imitateurs de l'insuline | |
| JPS5838421B2 (ja) | 分岐鎖状ケト酸のオルニチン及びアルギニン塩並びに肝臓及び腎臓障害の治療への使用 | |
| JPH06511244A (ja) | バナジウム組成物 | |
| SE457958B (sv) | Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositioner | |
| FI68970C (fi) | Foerfarande foer framstaellning av en ny medicinskt anvaendbarhemin-foerening | |
| CA2193551C (fr) | Agent eliminateur pour oxygene active et radicaux libres | |
| US7384558B2 (en) | Compositions capable of inhibiting reactive oxygen and carbonyl species | |
| CA2491763A1 (fr) | Methode de maitrise de la glycemie a l'aide de glucosamines n-acylees | |
| TEPPERMAN et al. | The role of hepatic detoxification in p-aminopropiophenone induced methemoglobinemia | |
| HU229185B1 (en) | L-acetyl carnitine and l-propionyl carnitine composition for the prevention and treatment of kidney dysfunctions and diseases | |
| AU2007209704B2 (en) | Novel salts of substituted 5-membered azacycle and use thereof in the treatment of diseases related to protein aging | |
| CN120554452A (zh) | 多肽及其解酒产品 | |
| JPH07285881A (ja) | アルコール代謝促進剤 | |
| FR2534589A1 (fr) | Procede pour la preparation d'une solution a usage pharmaceutique contenant un nouveau complexe mixte polynucleaire de fer iii comme ingredient actif | |
| US6261588B1 (en) | Prophylactics and remedies for renal diseases | |
| JPH0859485A (ja) | ３ーオキシゲルミルプロピオン酸化合物を主成分とするメイラード反応阻害剤 | |
| RU2177321C1 (ru) | Селеновое каротинопротеиновое органическое вещество для регулирования метаболических процессов (его варианты) | |
| WO2009045122A1 (fr) | Médicament destiné au traitement et à la prévention des complications liées au diabète sucré | |
| DK172797B1 (da) | Fremgangsmåde til fremstilling af et fysiologisk virksomt, vandopløseligt hæminkompleks samt anvendelse af dette til fremst | |
| JP2001206893A (ja) | 新規α−アミラーゼ阻害活性物質、その製造方法及びその用途 | |
| NO160923B (no) | Analogifremgangsmaate for fremstilling av fysiologisk virksomt, vannopploeselig hemin-arginat og hemin-lysinat. | |
| Shepard et al. | PRIMARY HYPEROXALURIA: III. Nutritional and Metabolic Studies in a Patient | |
| CA2183834C (fr) | Agents antihypertenseurs contenant des derives de pyrazolopyrimidine | |
| US6239178B1 (en) | Method of treating mammals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8406263-7 Format of ref document f/p: F |
|
| NUG | Patent has lapsed | ||
| NUG | Patent has lapsed |